ArticleBiochemical genetics2026
Novel Models to Predict Pregnancy for Patients Receiving In-Vitro-Fertilization Embryo Transfer: The Significance of Clinical Indicators and Key Gene Expression in the Endometrium.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to discover key genes associated with the in-vitro-fertilization embryo transfer (IVF‑ET) outcomes and develop new prediction models, as well as potential drugs. We enrolled the following infertile women who received IVF-ET between Sep 8, 2018, and Oct 19, 2021. The endometrial biopsy was performed for RNA sequencing. The differentially expressed genes (DEGs) were identified, based on which two models were developed for prediction of clinical pregnancy and live birth. Besides, we screened key pregnancy-lower and pregnancy-higher genes and identified candidate drugs that modulate the expression of key genes. Overall, 147 patients received IVF-ET, including 92 patients in the pregnancy group and 55 in the no-pregnancy group. We initially identified 180 differentially expressed genes (DEGs) between pregnancy and no-pregnancy groups, including 131 pregnancy-lower and 49 pregnancy-higher genes. After covariate-adjusted sensitivity analyses (age, RIF status, right-side AFC, and cycle type), 168 of these DEGs (93.3%) remained significant with consistent effect direction, and this 168-gene panel was used for all downstream predictive modelling and drug-repositioning analyses. Using the expression level of 17 genes and one clinical feature (recurrent implantation failure history), we developed a logistic regression model that achieved an apparent 100% classification accuracy in this internal dataset. Another live-birth prediction model was constructed using the expression of 20 genes and three clinical features (ovulation disorder, antral follicle count on the right side, and primary infertility), which also reached an apparent 100% accuracy in this internal cohort. Lastly, we screened key risk genes for drug mining, and four drugs may be beneficial for IVF‑ET: cyclosporine, acetaminophen, tretinoin, and estradiol. Combining key genes and clinical features, we developed two models with satisfactory apparent accuracy for predicting pregnancy and live birth. Based on the key genes, we further proposed four candidate drugs (cyclosporine, acetaminophen, tretinoin, and estradiol) that may have potential to improve IVF-ET outcomes and warrant further validation.
Indexed as
Identifiers
41870819What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.